These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 34043229)

  • 1. Postoperative Outcome of Patients Who Underwent Total Joint Replacement During the Tanezumab Phase 3 Osteoarthritis Development Program: A 24-Week Observational Study.
    Mont MA; Carrino JA; Nemeth MA; Burr A; Yamabe T; Viktrup L; Brown MT; West CR; Verburg KM
    Surg Technol Int; 2021 May; 38():467-477. PubMed ID: 34043229
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of adverse joint outcomes in patients with osteoarthritis treated with subcutaneous tanezumab.
    Carrino JA; McAlindon TE; Schnitzer TJ; Guermazi A; Hochberg MC; Conaghan PG; Brown MT; Burr A; Fountaine RJ; Pixton GC; Viktrup L; Verburg KM; West CR
    Osteoarthritis Cartilage; 2023 Dec; 31(12):1612-1626. PubMed ID: 37652258
    [TBL] [Abstract][Full Text] [Related]  

  • 3. When Is Osteonecrosis Not Osteonecrosis?: Adjudication of Reported Serious Adverse Joint Events in the Tanezumab Clinical Development Program.
    Hochberg MC; Tive LA; Abramson SB; Vignon E; Verburg KM; West CR; Smith MD; Hungerford DS
    Arthritis Rheumatol; 2016 Feb; 68(2):382-91. PubMed ID: 26554876
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Tanezumab on Joint Pain, Physical Function, and Patient Global Assessment of Osteoarthritis Among Patients With Osteoarthritis of the Hip or Knee: A Randomized Clinical Trial.
    Schnitzer TJ; Easton R; Pang S; Levinson DJ; Pixton G; Viktrup L; Davignon I; Brown MT; West CR; Verburg KM
    JAMA; 2019 Jul; 322(1):37-48. PubMed ID: 31265100
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Observed efficacy and clinically important improvements in participants with osteoarthritis treated with subcutaneous tanezumab: results from a 56-week randomized NSAID-controlled study.
    Neogi T; Hunter DJ; Churchill M; Shirinsky I; White A; Guermazi A; Omata M; Fountaine RJ; Pixton G; Viktrup L; Brown MT; West CR; Verburg KM
    Arthritis Res Ther; 2022 Mar; 24(1):78. PubMed ID: 35351194
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Subcutaneous tanezumab for osteoarthritis of the hip or knee: efficacy and safety results from a 24-week randomised phase III study with a 24-week follow-up period.
    Berenbaum F; Blanco FJ; Guermazi A; Miki K; Yamabe T; Viktrup L; Junor R; Carey W; Brown MT; West CR; Verburg KM
    Ann Rheum Dis; 2020 Jun; 79(6):800-810. PubMed ID: 32234715
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-Term Safety and Efficacy of Subcutaneous Tanezumab Versus Nonsteroidal Antiinflammatory Drugs for Hip or Knee Osteoarthritis: A Randomized Trial.
    Hochberg MC; Carrino JA; Schnitzer TJ; Guermazi A; Walsh DA; White A; Nakajo S; Fountaine RJ; Hickman A; Pixton G; Viktrup L; Brown MT; West CR; Verburg KM
    Arthritis Rheumatol; 2021 Jul; 73(7):1167-1177. PubMed ID: 33538113
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety of Low-Dose Tanezumab in the Treatment of Hip or Knee Osteoarthritis: A Systemic Review and Meta-analysis of Randomized Phase III Clinical Trials.
    Yu Y; Lu ST; Sun JP; Zhou W
    Pain Med; 2021 Mar; 22(3):585-595. PubMed ID: 33141224
    [TBL] [Abstract][Full Text] [Related]  

  • 9. General Safety and Tolerability of Subcutaneous Tanezumab for Osteoarthritis: A Pooled Analysis of Three Randomized, Placebo-Controlled Trials.
    Berenbaum F; Schnitzer TJ; Kivitz AJ; Viktrup L; Hickman A; Pixton G; Brown MT; Davignon I; West CR
    Arthritis Care Res (Hoboken); 2022 Jun; 74(6):918-928. PubMed ID: 33973384
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of tanezumab added on to diclofenac sustained release in patients with knee or hip osteoarthritis: a double-blind, placebo-controlled, parallel-group, multicentre phase III randomised clinical trial.
    Balanescu AR; Feist E; Wolfram G; Davignon I; Smith MD; Brown MT; West CR
    Ann Rheum Dis; 2014 Sep; 73(9):1665-72. PubMed ID: 23852695
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of serological biomarker profiles associated with total joint replacement in osteoarthritis patients.
    Arends RHGP; Karsdal MA; Verburg KM; West CR; Bay-Jensen AC; Keller DS
    Osteoarthritis Cartilage; 2017 Jun; 25(6):866-877. PubMed ID: 28115232
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of tanezumab monotherapy or combined with non-steroidal anti-inflammatory drugs in the treatment of knee or hip osteoarthritis pain.
    Schnitzer TJ; Ekman EF; Spierings EL; Greenberg HS; Smith MD; Brown MT; West CR; Verburg KM
    Ann Rheum Dis; 2015 Jun; 74(6):1202-11. PubMed ID: 24625625
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy, General Safety, and Joint Safety of Tanezumab in Japanese Patients with Osteoarthritis: Subgroup Analyses from Two Randomized, Phase 3 Studies.
    Miki K; Ohta M; Abe M; Yoshimatsu H; Fujii K; Ebata N; West CR; Brown MT; Pixton G; Isogawa N
    Pain Ther; 2022 Sep; 11(3):827-844. PubMed ID: 35538185
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of intravenous tanezumab for the symptomatic treatment of osteoarthritis: 2 randomized controlled trials versus naproxen.
    Ekman EF; Gimbel JS; Bello AE; Smith MD; Keller DS; Annis KM; Brown MT; West CR; Verburg KM
    J Rheumatol; 2014 Nov; 41(11):2249-59. PubMed ID: 25274899
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tanezumab reduces osteoarthritic knee pain: results of a randomized, double-blind, placebo-controlled phase III trial.
    Brown MT; Murphy FT; Radin DM; Davignon I; Smith MD; West CR
    J Pain; 2012 Aug; 13(8):790-8. PubMed ID: 22784777
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and Safety of Tanezumab on Osteoarthritis Knee and Hip Pains: A Meta-Analysis of Randomized Controlled Trials.
    Chen J; Li J; Li R; Wang H; Yang J; Xu J; Zha Z
    Pain Med; 2017 Feb; 18(2):374-385. PubMed ID: 28034979
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term safety and effectiveness of tanezumab as treatment for chronic low back pain.
    Gimbel JS; Kivitz AJ; Bramson C; Nemeth MA; Keller DS; Brown MT; West CR; Verburg KM
    Pain; 2014 Sep; 155(9):1793-1801. PubMed ID: 24937440
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Onset and maintenance of efficacy of subcutaneous tanezumab in patients with moderate to severe osteoarthritis of the knee or hip: A 16-week dose-titration study.
    Schnitzer TJ; Khan A; Bessette L; Davignon I; Brown MT; Pixton G; Prucka WR; Tive L; Viktrup L; West CR
    Semin Arthritis Rheum; 2020 Jun; 50(3):387-393. PubMed ID: 32252976
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase III placebo- and oxycodone-controlled study of tanezumab in adults with osteoarthritis pain of the hip or knee.
    Spierings ELH; Fidelholtz J; Wolfram G; Smith MD; Brown MT; West CR
    Pain; 2013 Sep; 154(9):1603-1612. PubMed ID: 23707270
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Subcutaneous tanezumab for osteoarthritis: Is the early improvement in pain and function meaningful and sustained?
    Berenbaum F; Langford R; Perrot S; Miki K; Blanco FJ; Yamabe T; Isogawa N; Junor R; Carey W; Viktrup L; West CR; Brown MT; Verburg KM
    Eur J Pain; 2021 Aug; 25(7):1525-1539. PubMed ID: 33728717
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.